Inaddition to assesses the efforts a show of hands states initiated with Pacific Growth Equities LLC, Avigencontinues to work with ProPharma Partners through an ongoing engagement toidentify European partnering opportunities for the AV411 assets.AV411 is a first-in-class orally bioavailable small molecule, a glial attenuatorthat suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6, andmay upregulate the anti-inflammatory cytokine IL-10. While considered a NewMolecular Entity (NME) in the United States and Europe, the drug was firstapproved in Japan more than 15 years ago. The drug has been prescribed to overone million patients for a different indication and has a good post-marketingsafety profile as reported in nearly 15,000 patients studied at the prescribeddoses Rush tickets .About AvigenAvigen is a biopharmaceutical company that has focused on identifying anddeveloping differentiated products to treat patients with serious neurologicaland other disorders. Avigen’s strategy is to identify, acquire and developopportunities that represent a positive return to Avigen’s shareholders.Avigen’s current potential product is AV411 for neuropathic pain and opioidwithdrawal and methamphetamine addiction. For more information about Avigen,consult the company’s website at Avigen, Inc.
logo is available at under the Private Securities Litigation Reform ActThe statements in this press release relating to Avigen’s strategy, objectivesand plans to identify, acquire and develop opportunities that represent apositive return to Avigen’s shareholders, its beliefs regarding the availabilityof strategic opportunities and potential value of monetizing AV411, futureactions that Avigen’s Board of Directors may take, and its expectations toreport on its progress at the upcoming quarterly conference call, areforward-looking statements . These statements are subject to risks anduncertainties that could cause actual results to differ materially from thoseprojected in these forward-looking statements, including the risk that Avigenwill not be able to acquire or develop such opportunities due to monetary,intellectual property, technological or other constraints adreniline . In addition, thereare many other risks and uncertainties inherent in the development of drugproducts alex lifeson Rush tickets . Other risks and uncertainties relating to Avigen are detailed inreports filed by Avigen with the Securities and Exchange Commission, includingAvigen’s quarterly report on Form 10-Q for the period ended September 30, 2008,under the caption “Risks Related to Our Business” in Item 2 of Part I of thatreport, which was filed with the SEC on November 10, 2008.Additional Information and Where to Find ItAvigen, its directors and certain of its officers and employees are potentialparticipants in a solicitation of proxies in connection with a special meetingof stockholders bravado . Information regarding the special interests of these directors,officers and employees will be included in any proxy statement filed by Avigenin connection with the special meeting.
In addition, Avigen files annual,quarterly and special reports, proxy, and other information with the SEC . Thesedocuments are available free of charge at the SEC’s web site at will file a proxy statement in connection with its special meeting ofstockholders closer to the heart . Avigen stockholders are strongly advised to read the proxystatement and the accompanying proxy card when they become available, as theywill contain important information, including information relating to theparticipants in such proxy solicitation different stages . Stockholders will be able to obtainthis proxy statement, any amendments or supplements to the proxy statement andother documents filed by Avigen with the SEC for free at the internet websitemaintained by the SEC at, Inc.Michael Coffee, Chief Business 1301 Harbor Bay Parkway, Alameda, CA 94502 distant early warning Rush tickets – rush . Leading Analyst Firm Includes Anacomp in Prestigious eDiscovery MarketscopeReportCompany Cited for CaseLogistix Review Platform and Document Services LegacySAN DIEGO, Jan.
14 /PRNewswire-FirstCall/ — Anacomp(R) Inc., a leadingbusiness process solutions company, today announced its inclusion in the”Marketscope for eDiscovery Software Product Vendors 2008″(1) published byGartner, a leading technology consulting firm . Now in its second year, thereport provides analysis of the electronic discovery technology market andevaluates offerings of leading vendors in the space dreamline . Anacomp andCaseLogistix(R), the company’s flagship litigation review platform, were ratedas “promising,” which is the highest rating available to vendors who areincluded in the report for the first time.According to the report, “Courts are requiring enterprises to improve theirhandling of information during litigation earthshine Rush tickets . The consequent spending oneDiscovery software technologies and service offerings is growing swiftly…and is forecast to grow between 25% and 35% annually through 2012.” The reportalso states that “Enterprises purchasing eDiscovery software can reduce thecosts of litigation by improving their control over unstructured andsemi-structured content.. . and can cut costs and risks by taking control oflitigation hold, litigation-hold tracking, file collection, file processing,and legal review instead of outsourcing these functions.” Finally, the reportstates that Gartner’s clients “report that the payback period for eDiscoveryinvestments is very short, on the order of three to six months afterimplementation takes place.”"We’re pleased to be included in the prestigious 2008 eDiscovery Marketscopeby Gartner, itself a very well-respected and influential analyst firm in theinformation technology realm,” said Wayne Ford, Anacomp’s Senior VicePresident of Marketing, Channels and Strategic Alliances.
HOW DOES SHEFIT INTO YOUR DISNEY PRINCESS FRANCHISE, AND HOW IS SHEDIFFERENT — OTHER THAN BEING AFRICAN-AMERICAN?Franklin: Our hope is that she will fit in as all the other princesses have fit in. In fact, Clemens has a 130 or higher ERA+, and more than 1,000 strikeouts in three different decades. He struggled a little in June, posting a 2-2 record with a 4 Rush tickets – rush .22 ERA He is 8-1 lifetime vs Rush tickets – rushlimbaugh . Most of us remember when he had that stellar early round in 2003 before losing in the finals.
